Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ASPH | Q12797 | 2/20 | 0.37 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7239604 | 0.82 | SIRT3 (0.44) | L3MBTL1TDP1KDM4ECCR1CCR5 | |
| SCHEMBL353204 | 0.81 | KDM4E (0.40) | L3MBTL1TDP1NAPRTLMNAP4HTM | |
| Hydrochloric Acid SCHEMBL4249059 | 0.79 | KDM4E (0.39) | L3MBTL1TDP1NAPRTLMNAP4HTM | |
| SCHEMBL30049082 | 0.79 | KDM4E (0.50) | CYP3A4ACHEL3MBTL1TDP1NAPRT | |
| SCHEMBL9504653 | 0.79 | KDM4E (0.39) | L3MBTL1TDP1NAPRTLMNAP4HTM | |
| SCHEMBL9684174 | 0.79 | KDM4E (0.50) | CYP3A4ACHEL3MBTL1TDP1NAPRT | |
| SCHEMBL7612137 | 0.79 | L3MBTL1 (0.38) | CYP3A4ACHEL3MBTL1TDP1NAPRT | |
| SCHEMBL30867527 | 0.79 | CA12 (0.47) | CYP3A4ACHEL3MBTL1TDP1LMNA | |
| SCHEMBL12515865 | 0.79 | CA12 (0.47) | CYP3A4ACHEL3MBTL1TDP1LMNA | |
| SCHEMBL7067358 | 0.78 | CA12 (0.50) | CYP3A4L3MBTL1TDP1NAPRTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228460-A1 | PROTEASE INHIBITORS AND METHODS OF MAKING SAME | VARIATIONAL AI INC (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| WO-2013006596-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | disclosed |
| EP-0225172-A1 | Process for the preparation of 5-chloro and 5-bromo-2-hydroxynicotinicacids | A.H. ROBINS COMPANY, INCORPORATED (US) | 1987-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228460-A1 | PROTEASE INHIBITORS AND METHODS OF MAKING SAME | ACE, ACE2, PRSS2 | CYP3A4 633/4885ACHE 390/4885L3MBTL1 1776/4885 |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, KCNB2, SCNN1B | CYP3A4 1026/4885ACHE 813/4885L3MBTL1 3824/4885 |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, SCNN1B, TRPV1 | CYP3A4 1339/4885ACHE 893/4885L3MBTL1 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.